How much passive income would a $10,000 investment in CSL shares generate?

Can this stock offer healthy dividends?

| More on:
A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owners of CSL Ltd (ASX: CSL) shares have benefited from enormous capital growth over the past decade, powered by its excellent profit growth in that time. This profit generation is enabling larger and larger passive income payouts.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL28 May 201428 May 2024Zoom ▾20152016201720182019202020212022202320242016201620182018202020202022202220242024www.fool.com.au

I like dividends because they allow investors to benefit from growth in the value of the business without having to sell shares to access that value.

CSL is one of the biggest companies on the ASX, with a market capitalisation of $135 billion. While it is a massive business, can it provide the same sort of dividend income as National Australia Bank Ltd (ASX: NAB), Westpac Banking Corp (ASX: WBC) or Rio Tinto Ltd (ASX: RIO)?

Let's look at how much passive income a $10,000 investment could generate with CSL shares.

Dividend potential of CSL shares

Dividends are paid for by the profit a company makes.

CSL's board decided to declare an FY23 final dividend of US$1.29 per share and a full-year dividend of US2.36 per share. Converted into Australian dollars, the total full-year dividend amounted to approximately A$3.59 per share, an increase of 13%. This came after the company generated net profit after tax (NPAT) of $2.19 billion in FY23.

The passive income growth continued in the FY24 first-half result, with the interim payout of US$1.19 per share. In Australian dollar terms, the half-year dividend was increased 12% to A$1.81.

The last two dividends paid by CSL amount to US$2.48 per share, or A$3.72 at the current exchange rate. That translates into a dividend yield of just 1.3%.

$10,000 investment

If I had $10,000 to invest in the ASX healthcare giant, I'd be able to buy 35 CSL shares.

Assuming CSL paid the same dividends over the next 12 months as the last 12 months, a shareholder would receive $130 of cash if they owned 35 CSL shares.

If its profit continues climbing, the company may be able to significantly increase its passive income in future financial years.

The broker UBS has forecast the company's dividend per share can increase to US$3.80 per share by FY28. If CSL did pay that amount, it would translate into a dividend yield of 2%, or around $200 in dollar terms.

While the prediction implies the CSL dividend could grow by more than 50% over the next four years, the dividend yield is still expected to be small by FY28.

CSL share price snapshot

Over the past year, the CSL share price has fallen more than 8%. According to UBS' profit projection, it's now trading at 30x FY24's estimated earnings.

Dividends may not be the most compelling reason to look at CSL shares, but its recovery from COVID-19 impacts and the product development pipeline could be more intriguing.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »